Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof
The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided.
1. An isolated peptide comprising
Granulin/epithelin precursor (GEP) granulin units F (amino acids 126-178 of SEQ ID NO: 1), A (amino acids 284-335 of SEQ ID NO: 1), and C (amino acids 366-416 of SEQ ID NO: 1); and
GEP linker units P3 (amino acids 179-205 of SEQ ID NO:1), P4 (amino acids 262-283 of SEQ ID NO:1), and P5 (amino acids 336-365 of SEQ ID NO:1), wherein the peptide antagonizes TNFR1 or TNFR2 signaling, and wherein the peptide is a mixed portion of the full-length GEP sequence.
2. An isolated peptide comprising:
at least ½F (amino acids 153-178 of SEQ ID NO: 1);
P3 (amino acids 179-205 of SEQ ID NO:1)
P4 (amino acids 262-283 of SEQ ID NO:1)
at least ½A (amino acids 284-304 of SEQ ID NO: 1);
P5 (amino acids 336-365 of SEQ ID NO:1); and
at least ½C (amino acids 366-392 of SEQ ID NO: 1);
wherein the peptide antagonizes TNFR1 or TNFR2 signaling, and wherein the peptide is a mixed portion of the full-length GEP sequence.
3. The isolated peptide of claim 1 , comprising:
(a) amino acids 126-205 of SEQ ID NO: 1;
(b) amino acids 262-335 of SEQ ID NO: 1; and
(c) amino acids 336-416 of SEQ ID NO: 1.
4. An isolated peptide comprising SEQ ID NO: 2 or a variant thereof having at least 90% sequence identity to SEQ ID NO: 2, wherein the peptide antagonizes TNFR1 or TNFR2 signaling.
5. The isolated peptide of claim 4 , wherein the peptide comprises SEQ ID NO: 2.
6. A pharmaceutical composition comprising the isolated peptide of claim 1 and a pharmaceutically acceptable carrier, vehicle, or diluent.
7. The composition of claim 6 further comprising one or more of an anti-inflammatory agent or compound, an anti-cancer agent or compound, and an immunomodulatory agent.
8. A pharmaceutical composition comprising the isolated peptide of claim 4 and a pharmaceutically acceptable carrier, vehicle, or diluent.
9. The composition of claim 8 further comprising one or more of an anti-inflammatory agent or compound, an anti-cancer agent or compound, and an immunomodulatory agent.
10. A pharmaceutical composition comprising the isolated peptide of claim 2 and a pharmaceutically acceptable carrier, vehicle, or diluent.
11. The composition of claim 10 further comprising one or more of an anti-inflammatory agent or compound, an anti-cancer agent or compound, and an immunomodulatory agent.